<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934671</url>
  </required_header>
  <id_info>
    <org_study_id>TD-REOX-2019</org_study_id>
    <nct_id>NCT03934671</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of an Antioxidant Dressing in Chronic Wound Healing</brief_title>
  <acronym>REOX</acronym>
  <official_title>Evaluation of the Efficacy of an Antioxidant Dressing in Chronic Wound Healing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jaén</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Histocell, S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Andalusian Health Service: District Poniente Almería.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Andalusian Health Service: District Jaén</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Andalusian Health Service: District Jaén-Nordeste</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Andalusian Health Service: Health Management Area Este of Málaga-Axarquía.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Jaén</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effect of antioxidant dressing (active product) on
      chronic wound healing with the use of non-active wound dressing for healing in a moist
      environment (standard clinical practice) in patients with hard-to-heal wounds
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the score of the RESVECH 2.0 scale for chronic wound healing monitoring</measure>
    <time_frame>At baseline, after 2 week, after 4 week, after 6 week and after 8 week</time_frame>
    <description>The RESVECH 2.0 is a scale for monitoring the cicatrization of the wound. It has 6 items: size of the lesion, depth/tissue concerned, edges, type of tissue in the wound bed, exudate, infection/inflammation. The scale is scored numerically and can score ranging from 0 to 35 points, wound healed and the worst possible lesion respectively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound size reduction</measure>
    <time_frame>At baseline, after 2 week, after 4 week, after 6 week and after 8 week</time_frame>
    <description>Difference in wound area between first and last dressing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time required to achieve 50% reduction in wound size</measure>
    <time_frame>Change from baseline to 8 weeks of follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to removal of non-viable tissue from wound bed</measure>
    <time_frame>At baseline, after 2 week, after 4 week, after 6 week and after 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of completely healed wounds</measure>
    <time_frame>At baseline, after 2 week, after 4 week, after 6 week and after 8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain level</measure>
    <time_frame>At baseline, after 2 week, after 4 week, after 6 week and after 8 week</time_frame>
    <description>The visual analogue scale (VAS) is commonly used as the outcome measure for patient´s pain. It is usually presented as a 100-mm horizontal line on which pain intensity is represented by a point between the extremes of &quot;no pain at all&quot; and &quot;worst pain imaginable.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area of wound with bacterial load</measure>
    <time_frame>At baseline, after 2 week, after 4 week, after 6 week and after 8 week</time_frame>
    <description>clinical signs of infection and/or measurement of surfaces with bacteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Hard-to-heal Wounds</condition>
  <arm_group>
    <arm_group_label>Antioxidant dressing (active product)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care dressing (standard clinical practice)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Antioxidant dressing (active product)</intervention_name>
    <description>Antioxidant dressing (active product), covered with secondary dressing. Compression bandage if necessary.
Device: Reoxcare®</description>
    <arm_group_label>Antioxidant dressing (active product)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Usual care dressing that create a moist environment (standard clinical practice)</intervention_name>
    <description>Usual care dressing; moist environment dressing chosen from the study centres' formulary (hydrocolloid, alginate, polyurethane foam dressings, silver dressings). Compression bandage if necessary</description>
    <arm_group_label>Usual care dressing (standard clinical practice)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years of age.

          -  Patients with leg ulcers (venous, ischemic, traumatic or diabetic foot ulcer).

          -  Patients with dehisced surgical wounds healing by second intention.

          -  Patients with pressure ulcers.

          -  Wound area between 1 and 250 cm2.

        Exclusion Criteria:

          -  Systemic inflammatory disease or oncological disease.

          -  Wounds with clinical signs of infection.

          -  Terminal situation (life expectancy less than 6 months).

          -  Ulcers from other etiologies: tumours, infectious.

          -  Wounds treated with negative pressure therapy.

          -  Pregnancy.

          -  History of sensitivity or allergy to any of the components of the study dressing.

        In addition, criteria for withdrawal from the study will be considered:

          -  Worsening of the wound according to the clinical judgment of the professional
             (appearance of clinical signs of infection or others).

          -  Appearance of allergies or hypersensitivity to the dressing.

          -  Death.

          -  Hospital admission that interrupts or complicates the continuity of care in the
             Nursing Consultation.

          -  Transfer to another Health District where there can be no continuity of care with the
             active dressing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Inés María Comino-Sanz</last_name>
    <phone>953213627</phone>
    <email>icomino@ujaen.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universidad de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inés María Comino-Sanz</last_name>
      <email>icomino@ujaen.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/29244974</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/26140672</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Castro B, Bastida FD, Segovia T, López Casanova P, Soldevilla JJ, Verdú-Soriano J. The use of an antioxidant dressing on hard-to-heal wounds: a multicentre, prospective case series. J Wound Care. 2017 Dec 2;26(12):742-750. doi: 10.12968/jowc.2017.26.12.742.</citation>
    <PMID>29244974</PMID>
  </reference>
  <reference>
    <citation>Castro B, Palomares T, Azcoitia I, Bastida F, del Olmo M, Soldevilla JJ, Alonso-Varona A. Development and preclinical evaluation of a new galactomannan-based dressing with antioxidant properties for wound healing. Histol Histopathol. 2015 Dec;30(12):1499-512. doi: 10.14670/HH-11-646. Epub 2015 Jul 3.</citation>
    <PMID>26140672</PMID>
  </reference>
  <reference>
    <citation>Comino-Sanz IM, López-Franco MD, Castro B, Pancorbo-Hidalgo PL. Antioxidant dressing therapy versus standard wound care in chronic wounds (the REOX study): study protocol for a randomized controlled trial. Trials. 2020 Jun 8;21(1):505. doi: 10.1186/s13063-020-04445-5.</citation>
    <PMID>32513260</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 24, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jaén</investigator_affiliation>
    <investigator_full_name>Inés María Comino-Sanz</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Chronic wound</keyword>
  <keyword>Wound healing</keyword>
  <keyword>Hard-to-heal wounds</keyword>
  <keyword>Antioxidant dressing</keyword>
  <keyword>Oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

